Quantcast
Last updated on April 21, 2014 at 8:55 EDT

Latest Postoperative nausea and vomiting Stories

2013-10-30 04:21:57

CAMBRIDGE, England, October 30, 2013 /PRNewswire/ -- Acacia Pharma, a pharmaceutical company specialising in the development of drugs for supportive care, announces the initiation of a Phase II study of APD403 in the prevention of chemotherapy-induced nausea & vomiting (CINV). CINV remains a clinically significant problem in cancer patients receiving emetogenic chemotherapy despite the availability of a range of anti-emetic medications. CINV occurs in approximately...

2013-10-29 08:32:28

Study Demonstrates High Statistical Significance in Both Primary Endpoints of Reduction of Opioid-Induced Nausea/Vomiting and Pain JUPITER, Fla., Oct. 29, 2013 /PRNewswire/ -- Charleston Laboratories, Inc, an emerging specialty pharmaceutical company focused on the research and development of novel pain products, announced today that it has completed its Phase 3 clinical trial of CL-108 at the midway point. (CL-108 is a strong pain-reliever designed to also prevent nausea and...

2013-10-09 12:25:48

JUPITER, Fla., Oct. 9, 2013 /PRNewswire/ -- Charleston Laboratories, Inc, an emerging specialty pharmaceutical company focused on the research and development of novel pain products that prevent or significantly reduce nausea and vomiting related to opioid analgesics and other pain associated disease states, announced today the commencement of a research program to evaluate anti-emetic effects on opioid-induced hyperalgesia and physical dependence with the Anesthesiology, Pain and...

2013-09-17 04:22:19

CAMBRIDGE, England, September 17, 2013 /PRNewswire/ -- Acacia Pharma, a pharmaceutical company specialising in the development of drugs for supportive care, announces the initiation of two pivotal Phase 3 studies of APD421 in the prevention of post-operative nausea & vomiting (PONV). PONV remains a clinically significant problem in patients undergoing major surgery, despite the availability of a range of anti-emetic medications. The Phase 3 studies are taking place...

2013-08-29 12:26:09

Product Line Momentum is Building FRANKLIN LAKES, N.J., Aug. 29, 2013 /PRNewswire/ -- BD Rx Inc., a wholly-owned subsidiary of leading global medical technology company BD (Becton, Dickinson and Company) (NYSE: BDX), announced today that the U.S. Food and Drug Administration (FDA) has approved the third drug to be offered in the new BD Simplist(TM) line of ready-to-administer prefilled generic injectables. The third BD Simplist product to launch is Ondansetron Injection, USP 4mg/2mL (2mg/mL),...

2013-04-16 12:26:32

CHARLESTON, S.C., April 16, 2013 /PRNewswire/ -- Charleston Laboratories, Inc, an emerging specialty pharmaceutical company focused on the research and development of novel pain products that prevent or significantly reduce nausea and vomiting related to opioid analgesics and other pain associated disease states, announced today the U.S. Food and Drug Administration has granted its request for a Pre-IND meeting to discuss the proposed Investigational New Drug, CL-H1T, as a novel treatment for...

2012-07-25 02:28:06

NEWPORT, R.I., July 25, 2012 /PRNewswire/ -- Migraine can be a disabling neurological disorder, often aggravated by accompanying nausea. Stimulation of the acupoint PC6 Neiguan, an approach to controlling nausea adopted by traditional Chinese medicine, has never been documented by published clinical studies in medical literature for the control of migraine-related nausea, until now. Published in the May 2012 Neurological Sciences (journal of the Italian Neurological Society)(1), "Acupressure...

2012-05-28 02:20:47

CAMBRIDGE, England, May 28, 2012 /PRNewswire/ -- Acacia Pharma announces positive results from its Phase II study of APD421, in the prevention of post-operative nausea & vomiting (PONV). The study showed that APD421 significantly reduced the incidence of nausea and vomiting compared to placebo in adult surgical patients at moderate-to-high risk of suffering PONV. Vomiting and especially nausea remain a major problem for patients after surgical operations, despite the...

2011-07-11 07:33:00

WARREN, N.J., July 11, 2011 /PRNewswire/ -- MonoSol Rx, a specialty pharmaceutical company and the developers of the PharmFilm® technology platform, in collaboration with APR Applied Pharma Research s.a. of Switzerland ("APR"), announced today that its FDA-approved anti-emetic Zuplenz (Ondansetron) oral soluble film is available for licensing to new commercial partners. The Company made the strategic decision to reacquire the commercial rights to Zuplenz from Strativa...

2010-11-04 14:43:21

Vomiting is unpleasant. Nearly 30% of all patients suffer from nausea and vomiting after surgery. The financial repercussions of this are longer patient stays in the recovery room, with increased need for personnel. Appropriate prophylaxis and treatment can prevent postoperative nausea and vomiting. In a systematic review of the literature, Dirk Rsch and co-authors investigate how treatment recommendations for nausea after general anesthesia can be improved (Dtsch Arztebl Int 2010; 107[42]:...